KRAS mutation testing in colorectal cancer: the model for molecular pathology testing in the future
Colorectal Cancer · 2016
DOI: 10.2217/crc-2015-0009 ↗Kurz gefasst
Fachartikel in der Zeitschrift Colorectal Cancer, 2016. Verfasst von Stephen Q Wong und 2 weiteren Autor:innen. Die Arbeit nennt 48 Literaturangaben.
Abstract (Originalsprache)
Somatic mutations in the KRAS gene often occur in colorectal cancer (CRC) and are predictive for poor response to EGFR blockade therapy. Over the past decade, routine detection of KRAS mutations has been employed in many diagnostic centers using a range of methodological approaches including Sanger sequencing, pyrosequencing, high-resolution melt analysis and more recently, next-generation sequencing approaches. This article highlights the clinical relevance of KRAS-mutated CRCs, examines advantages and disadvantages of various detection methods and highlights the considerations that are critical for an accurate, rapid and efficient workflow to detect KRAS and other RAS mutations in CRC presently and in the future.
Zitieren
APA
Wong, S. Q., Scott, R., & Fox, S. B. (2016). KRAS mutation testing in colorectal cancer: the model for molecular pathology testing in the future. Colorectal Cancer. https://doi.org/10.2217/crc-2015-0009
Vancouver
Wong SQ, Scott R, Fox SB. KRAS mutation testing in colorectal cancer: the model for molecular pathology testing in the future. Colorectal Cancer. 2016. doi:10.2217/crc-2015-0009
BibTeX
@article{Wong2016,
author = {Wong, Stephen Q and Scott, Rodney and Fox, Stephen B},
title = {KRAS mutation testing in colorectal cancer: the model for molecular pathology testing in the future},
journal = {Colorectal Cancer},
year = {2016},
doi = {10.2217/crc-2015-0009}
}
EUVIMED